J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia Options Price in $280 Billion Earnings Swing 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tesla Raises Cybertruck Prices by $5,000 in US 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
(4) - EconoTimes)
Add as a preferred source on Google
EMERYVILLE, Calif., May 01, 2018 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.
The awards were made on May 1, 2018, under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 31,500 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $40.15, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About Zogenix
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
Media: Rachel Lipsitz
Public Relations, INC Research/inVentivHealth
858-449-9575 | [email protected]
